Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

Published:2018-01 Issue:1 Volume:29 Page:250-255
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Pollack M.H.,Betof A.,Dearden H.,Rapazzo K.,Valentine I.,Brohl A.S.,Ancell K.K.,Long G.V.,Menzies A.M.,Eroglu Z.,Johnson D.B.,Shoushtari A.N.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/1/250/24170058/mdx642.pdf

Reference15 articles.

1. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials;Korn;J Clin Oncol,2008

2. Overall survival and durable responses in patients with braf v600-mutant metastatic melanoma receiving dabrafenib combined with trametinib;Long;J Clin Oncol,2016

3. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab;Topalian;J Clin Oncol,2014

4. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma;Weber;J Clin Oncol,2017

5. Toxicities of immunotherapy for the practitioner;Weber;J Clin Oncol,2015

Cited by 321 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. Psoriasiform rash following maculopapular eruption during the continued administration of pembrolizumab;Anais Brasileiros de Dermatologia;2024-09

3. Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study;Annals of Oncology;2024-09

4. Peripheral nervous system immune-related adverse events due to checkpoint inhibition;Nature Reviews Neurology;2024-08-09

5. The development of anti-PD-1 antibody-induced spinal cord injury in bone marrow transplant C57BL/6 Rag1 ^-/- mouse model;Immunotherapy;2024-08-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3